<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853450</url>
  </required_header>
  <id_info>
    <org_study_id>D1700C00004</org_study_id>
    <secondary_id>EudraCT no. 2008-007030-21</secondary_id>
    <nct_id>NCT00853450</nct_id>
  </id_info>
  <brief_title>Bleeding Time Study With AZD6482, Clopidogrel and ASA</brief_title>
  <official_title>A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on
      bleeding time when taken together with low-dose ASA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary Bleeding Time (CBT)</measure>
    <time_frame>Prior to first dose in each treatment period, on study day 6 and 7 in treatment period A and on study day 7 in treatment period B</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on bleeding</measure>
    <time_frame>Prior to first dose in each treatment period, twice on study day 6 and three times on study day 7 in treatment period A and twice on study day 7 in treatment period B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Prior to AZD6482 infusion and repeatedly during 6 hours after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, ECG, safety lab)</measure>
    <time_frame>Repeatedly during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Antiplatelet Effect</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD6482 on top of ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel on top of ASA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6482</intervention_name>
    <description>Single intravenous infusion during a maximum of 5 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Plavix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>75 mg orally once daily during 7 days in each treatment arm</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Trombyl®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg,
             inclusive

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Personal or family history of bleeding disorders, or reasonable suspicion of vascular
             malformations, including aneurysms.

          -  Acute illness, surgical procedure or trauma from 2 weeks before pre-entry visit until
             the first baseline visit or clinically significant abnormalities in clinical
             chemistry, haematology, urinalysis or supine BP or pulse

          -  Known impaired glucose tolerance, known galactose intolerance, total lactase
             deficiency or glucose-galactose malabsorption or known or suspected Gilbert's syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Held</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter Held, Medical Science Director, Early Thrombosis &amp; Haemostasis</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Antiplatelet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

